Participation of coenzyme Q10 in the rejection development of the transplanted heart: a clinical study
J Kucharská, A Gvozdjáková, S Mizera, Z Braunová, Z Schreinerová, E Schrameková, I Pechán, J Fabián, J Kucharská, A Gvozdjáková, S Mizera, Z Braunová, Z Schreinerová, E Schrameková, I Pechán, J Fabián
Abstract
Coenzyme Q10 and alpha-tocopherol concentrations were assessed in 28 endomyocardial biopsies from 22 patients and in 61 blood samples from 31 patients after heart transplantation with histologically confirmed signs of rejection. The values were compared to the group of 14 patients with cardiomyopathies of unclear etiology as candidates for heart transplantation. Blood analyses were also compared with 50 healthy persons. Myocardial and blood coenzyme Q10 concentrations were already significantly decreased in the incipient phase of rejection (degree 0-1) and also in rejection phase 1 and 2. In patients without rejection signs myocardial and blood coenzyme Q10 values were similar to those of cardiomyopathic patients. No significant differences were found in alpha-tocopherol concentrations in relation to signs of rejection. Increased plasma lipid peroxidation quantified as malondialdehyde production was detected in all groups of transplanted patients. The results contribute to the explanation of some pathobiochemical mechanisms participating in the rejection development of the transplanted heart.
Source: PubMed